Work

Abstract A03: Comprehensive predictive biomarker evaluation in two phase II clinical trials of the PI3K/mTOR inhibitor GDC-0980 in metastatic renal cell carcinoma and advanced endometrial cancer

Year: 2015

Type: conference-abstract

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1538-8514.pi3k14-a03

Authors: Jill M. Spoerke, Vicky Makker, Carol Aghajanian, Powles Thomas, Robert J. Motzer, Jennifer O. Lauchle, Hema Parmar, Houston Gilbert, Wei Lin, Bridget O'Keeffe, Michelle Byrtek, Hartmut Koeppen, Yulei Wang, Shan Lu, Ling-Yuh Huw, Garret M. Hampton, Mark R. Lackner

Institutions: Genentech, Memorial Sloan Kettering Cancer Center, St Bartholomew's Hospital

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2490701731

Cites:

Cited by: 2

Related to: 10